Neoadjuvant atezolizumab for resectable non-small cell lung cancer: An open-label, single-arm phase II trial

Authors

Jamie E Chaft, Weill Cornell Medical College
G Alexander Patterson, Washington University School of Medicine in St. Louis
Saiama N Waqar, Washington University School of Medicine in St. Louis
et al.

Journal

Nature Medicine

Publication Date

10-1-2022

Volume

28

Issue

10

First Page

2155

Last Page

2161

Document Type

Open Access Publication

DOI

10.1038/s41591-022-01962-5

Rights and Permissions

Chaft, J.E., Oezkan, F., Kris, M.G. et al. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med 28, 2155–2161 (2022). https://doi.org/10.1038/s41591-022-01962-5 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Recommended Citation

Chaft, Jamie E; Patterson, G Alexander; Waqar, Saiama N; and et al., "Neoadjuvant atezolizumab for resectable non-small cell lung cancer: An open-label, single-arm phase II trial." Nature Medicine. 28, 10. 2155 - 2161. (2022).
https://digitalcommons.wustl.edu/oa_4/504